From Data Factory to Better Drugs: Automated Design-Make-Test-Learn Labs

"This is only possible because we control the design, make, and test steps within one connected system rather than handing off between disconnected tools and teams." Once molecules are designed in silico, they must be synthesized and tested in the real world. In Part 7 of our platform series, VP of Pharmacology Martin Redhead, Ph.D., explains how these candidate designs move directly into our automated DMTL (Design, Make, Test, Learn) labs. Recursion’s automated chemistry platform goes far beyond simple one-pot reactions. We execute complex, multi-step medicinal chemistry at scale. Advanced automation handles the workup, purification, and digital sample tracking for thousands of compounds, creating a digital record of every single experiment. Our in-house AI agents take this a step further by actively helping scientists plan efficient synthetic routes. Because we control the entire design, make, and test lifecycle within one fully integrated system, we completely eliminate the friction and time lost handing off data between disconnected teams. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #ComputationalChemistry #DrugDiscovery #MachineLearning